A new dawn in the treatment of dyslipidemia: cardiovascular risk reduction through emerging science and proven clinical results. Introduction.
Brewer
H Bryan
HB
Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md, USA.
D015415:Biomarkers / Q000097:blood; D003327:Coronary Disease / Q000209:etiology; D006801:Humans; D006949:Hyperlipidemias / Q000175:diagnosis / Q000628:therapy; D007249:Inflammation / Q000209:etiology / Q000628:therapy; D040242:Risk Reduction Behavior
D015415:Biomarkers